Razadyne ER (Galantamine Hydrobromide powder) at https://www.wisepowder.com/product-details/69353-21-5/ is a cholinesterase inhibitor used to treat mild to severe dementia caused by Alzheimer’s disease. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain. Razadyne ER is also available as a generic.
Hydrobromide of galantamine General Information
Galantamine inhibits acetylcholinesterase competitively and reversibly, raising the concentration and improving the action of acetylcholine (Ach). Galantamine is also a ligand for nicotinic acetylcholine receptors, increasing presynaptic Ach release and activating postsynaptic receptors.
This agent can improve neurocognitive function in Alzheimer’s disease patients with mild to moderate disease and reduce abstinence-induced cognitive symptoms that lead to relapse.
Experience of Clinical Trials
Since clinical trials are performed in such a broad range of circumstances, adverse reaction rates seen in one drug’s clinical trials cannot be specifically compared to rates seen in another drug’s clinical trials. They may not represent rates seen in reality. Nausea, vomiting, dizziness, headache, diarrhea, and reduced appetite were the most common adverse reactions in galantamine-treated patients in double-blind clinical trials (5%).
Vomiting (3.3 percent), nausea (6.2 percent), reduced appetite (1.5 percent), and dizziness were the most common adverse reactions associated with discontinuation (1% ) in galantamine-treated patients from double-blind clinical trials (1.3 percent ).
During the dose-escalation phase, the majority of these adverse reactions occurred. The median period of nausea in patients who suffered the most common adverse reaction, nausea, was 5-7 days.
Other Galantamine Adverse Reactions Seen in Clinical Trials
In the above double-blind, placebo-controlled clinical trial data sets, the following adverse reactions occurred in less than 1% of all galantamine-treated patients (N=3956). All adverse reactions recorded at any frequency rate in patients (N=1454) who participated in open-label studies are included in the following.
Galantamine’s extended-release capsule and immediate-release tablet formulations were tested in 3956 galantamine-treated patients in eight placebo-controlled clinical trials and 1454 participants in five open-label clinical studies with mild to moderate Alzheimer’s dementia. In clinical trials, the safety profile of once-daily extended-release galantamine therapy was close to that of tablets in frequency and nature. This section’s data comes from a combination of pooled double-blind trials and pooled open-label data.
History of Galantamine Hydrobromide Powder
Galantamine is a form of galantamine. Galantamine hydrobromide powder is the hydrobromide salt form of galantamine, a tertiary alkaloid found in the bulbs and flowers of Narcissus and other Amaryllidaceae genera that has anticholinesterase and neurocognitive-enhancing properties.
Mechanism of Action of Galantamine Hydrobromide
Galantamine is a phenanthrene alkaloid that inhibits acetylcholinesterase in a reversible, competitive manner. Its structure differs from that of other acetylcholinesterase inhibitors. Galantamine’s mechanism of action is based on the reversible inhibition of acetylcholinesterase, which prevents acetylcholine hydrolysis and increases acetylcholine concentration at cholinergic synapses. Galantamine binds to nicotinic acetylcholine receptors allosterically and can potentiate the action of agonists (such as acetylcholine) at these receptors. If you want to get more information, you can read this post.
For more articles visit this website
